Investment Thesis Map
We mined Johnson & Johnson’s acquisitions, investments, and partnerships to discern the company's strategic priorities.
Johnson & Johnson (J&J) is the most valuable pharmaceutical company in the world, with a $452B valuation. Over the last 2 years, J&J has forged dozens of strategic business partnerships, invested in over 50 different companies, launched a number of partnerships, and made a handful of acquisitions.
Many of these relationships have served to complement J&J’s core offerings across consumer products, orthopedics (Ethicon), and pharmaceuticals (Janssen). For example, over the past 2 years, J&J has announced investments in 3 consumer health companies – including Thirty Madison. It has also made a number of investments and partnerships in digital surgery — notably, it acquired Verb Surgical in December 2019. Additionally, Janssen, J&J’s pharmaceutical subsidiary, has partnered with AI and quantum computing startups, like Qu&Co, to improve drug R&D.
Using CB Insights data, we uncovered the 6 most important strategic priorities highlighted by J&J’s recent acquisitions, investments, and partnerships. We then categorized companies by their business relationships with J&J across these priorities.
- Consumer health
- Diagnostics
- Digital therapeutics
- Drug discovery
- Real-world data
- Surgical support
